Influenza Vaccine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

The global influenza vaccine market is witnessing strong and sustained growth, driven by increasing seasonal outbreaks, rising government immunization programs, and continuous advancements in vaccine technologies. According to industry estimates, the market was valued at USD 9.2 billion in 2025 and is projected to reach USD 9.96 billion in 2026, ultimately expanding to USD 22.49 billion by 2034, registering a CAGR of 10.72% during 2026-2034.

Market Size and Value Overview

The steady rise in market value reflects the growing global emphasis on preventive healthcare and vaccination coverage. Influenza continues to cause significant global health burdens, with the World Health Organization (WHO) reporting approximately 3 to 5 million severe influenza cases annually, leading to 290,000 to 650,000 deaths worldwide. This increasing disease burden has directly influenced vaccine demand across both developed and developing economies.

In 2025, North America dominated the global market with a value of USD 4.95 billion, accounting for 53.79% of the total global share. The region is expected to maintain strong growth due to advanced healthcare infrastructure, early adoption of innovative vaccines, and strong public awareness campaigns led by agencies such as the Centers for Disease Control and Prevention (CDC) and the WHO Global Influenza Surveillance and Response System (GISRS).

Regional Insights

North America remains the leading region, supported by high influenza incidence and strong vaccine adoption rates. The U.S. alone recorded approximately 37.2 million influenza cases in 2021, reinforcing the need for annual immunization programs.

Europe follows as the second-largest market, supported by government procurement initiatives and large-scale vaccination programs. The region accounted for USD 2.45 billion in 2025 and is expected to reach USD 2.63 billion in 2026. Asia Pacific, on the other hand, is emerging as the fastest-growing region due to expanding healthcare access, large population base, and increasing government vaccination campaigns, particularly in China and India.

Market Drivers

A key growth driver is increasing government support for immunization programs. Organizations such as the CDC, WHO, and national health ministries are actively promoting vaccination through public awareness campaigns and free immunization drives. For example, initiatives like "Help Them Fight Flu" have significantly improved vaccination coverage among children and high-risk populations.

Another major driver is rising research and development investment. Pharmaceutical companies are focusing on next-generation vaccines, including mRNA-based and combination vaccines that target both influenza and COVID-19. In 2021, researchers at Duke University developed an experimental mRNA-based combination vaccine targeting both viruses, highlighting future innovation potential.

Industry Developments and Key Companies

The influenza vaccine market is highly competitive, with major pharmaceutical players investing in manufacturing expansion and advanced vaccine platforms.

Key industry participants include:

Sanofi, a global leader in influenza vaccines, strengthened its position through approvals of Fluzone High-Dose Quadrivalent and Flublok Quadrivalent for the 2022-2023 flu season.
GlaxoSmithKline plc plays a significant role in European vaccine supply agreements and large-scale production initiatives.
AstraZeneca continues to contribute through its flu vaccine innovations, including nasal spray vaccine technologies.
CSL Limited is investing heavily in R&D facilities and next-generation mRNA-based influenza vaccines.
SINOVAC expanded global vaccine production capabilities through international investments.
Abbott and Viatris Inc. continue to support global distribution networks.
BIKEN Co., Ltd. contributes significantly to influenza vaccine development in Japan.

Market Segmentation Trends

Quadrivalent vaccines dominate the market due to broader protection against multiple influenza strains, accounting for the largest share in 2025. Inactivated vaccines also lead the segment with over 92% share in 2026 due to their safety profile and wide regulatory acceptance.

By age group, adult vaccination holds a significant share due to high-risk elderly populations, while pediatric vaccination is expected to grow rapidly due to increasing immunization coverage in developing countries.

Conclusion

Between 2025 and 2034, the influenza vaccine market is expected to experience strong expansion driven by rising disease prevalence, technological advancements in vaccine development, and increasing global immunization efforts. With the market projected to grow from USD 9.2 billion in 2025 to USD 22.49 billion in 2034, the industry presents significant opportunities for pharmaceutical companies and public health organizations worldwide.

Segmentation By Type

Inactivated
Live Attenuated

By Valency

Quadrivalent
Trivalent

By Age Group

Pediatric
Adults

By Distribution Channel

Hospital & Retail Pharmacies
Government Suppliers
Others

By Region

North America (By Type, By Valency, By Age Group, By Distribution Channel, and By Country)
- U.S. (By Valency)
- Canada (By Valency)
Europe (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
- U.K. (By Valency)
- Germany (By Valency)
- France (By Valency)
- Italy (By Valency)
- Spain (By Valency)
- Scandinavia (By Valency)
- Rest of Europe (By Valency)
Asia Pacific (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
- Japan (By Valency)
- Korea (By Valency)
- China (By Valency)
- India (By Valency)
- Australia (By Valency)
- Rest of Asia Pacific (By Valency)
Latin America (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
- Brazil (By Valency)
- Mexico (By Valency)
- Rest of Latin America (By Valency)
Middle East & Africa (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
- GCC (By Valency)
- South Africa (By Valency)
- Rest of Middle East & Africa (By Valency)

Product Code: FBI101896

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Snapshot of Influenza Vaccine Rate - For Key Countries, 2025
4.2. Annual Disease Burden of Influenza - For Key Countries/ Regions, 2025/2025
4.3. New Product Launches, By Key Players
4.4. Influenza Vaccination Campaigns/Programs Undertaken by Government
4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
4.6. Pricing Analysis - By Key Brand/Key Players, By Key Countries, 2025/2025
4.7. Snapshot of Pipeline Analysis of Influenza Vaccines
4.8. Impact of COVID-19 on the Market

5. Global Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Inactivated
- 5.1.2. Live Attenuated
5.2. Market Analysis, Insights and Forecast - By Valency
- 5.2.1. Quadrivalent
- 5.2.2. Trivalent
5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa

6. North America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Inactivated
- 6.1.2. Live Attenuated
6.2. Market Analysis, Insights and Forecast - By Valency
- 6.2.1. Quadrivalent
- 6.2.2. Trivalent
6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital & Retail Pharmacies
- 6.4.2. Government Suppliers
- 6.4.3. Others
6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
  - 6.5.1.1. By Valency
- 6.5.2. Canada
  - 6.5.2.1. By Valency

7. Europe Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Inactivated
- 7.1.2. Live Attenuated
7.2. Market Analysis, Insights and Forecast - By Valency
- 7.2.1. Quadrivalent
- 7.2.2. Trivalent
7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital & Retail Pharmacies
- 7.4.2. Government Suppliers
- 7.4.3. Others
7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
  - 7.5.1.1. By Valency
- 7.5.2. Germany
  - 7.5.2.1. By Valency
- 7.5.3. France
  - 7.5.3.1. By Valency
- 7.5.4. Italy
  - 7.5.4.1. By Valency
- 7.5.5. Spain
  - 7.5.5.1. By Valency
- 7.5.6. Scandinavia
  - 7.5.6.1. By Valency
- 7.5.7. Rest of Europe
  - 7.5.7.1. By Valency

8. Asia Pacific Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Inactivated
- 8.1.2. Live Attenuated
8.2. Market Analysis, Insights and Forecast - By Valency
- 8.2.1. Quadrivalent
- 8.2.2. Trivalent
8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital & Retail Pharmacies
- 8.4.2. Government Suppliers
- 8.4.3. Others
8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
  - 8.5.1.1. By Valency
- 8.5.2. China
  - 8.5.2.1. By Valency
- 8.5.3. India
  - 8.5.3.1. By Valency
- 8.5.4. Australia
  - 8.5.4.1. By Valency
- 8.5.5. Korea
  - 8.5.5.1. By Valency
- 8.5.6. Rest of Asia Pacific
  - 8.5.6.1. By Valency

9. Latin America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Inactivated
- 9.1.2. Live Attenuated
9.2. Market Analysis, Insights and Forecast - By Valency
- 9.2.1. Quadrivalent
- 9.2.2. Trivalent
9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital & Retail Pharmacies
- 9.4.2. Government Suppliers
- 9.4.3. Others
9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
  - 9.5.1.1. By Valency
- 9.5.2. Mexico
  - 9.5.2.1. By Valency
- 9.5.3. Rest of Latin America
  - 9.5.3.1. By Valency

10. Middle East & Africa Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Inactivated
- 10.1.2. Live Attenuated
10.2. Market Analysis, Insights and Forecast - By Valency
- 10.2.1. Quadrivalent
- 10.2.2. Trivalent
10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital & Retail Pharmacies
- 10.4.2. Government Suppliers
- 10.4.3. Others
10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC Countries
  - 10.5.1.1. By Valency
- 10.5.2. South Africa
  - 10.5.2.1. By Valency
- 10.5.3. Rest of Middle East & Africa
  - 10.5.3.1. By Valency

11. Competitive Analysis

11.1. Global Market Share Analysis (2025)
11.2. Company Profiles
- 11.2.1. AstraZeneca
  - 11.2.1.1. Overview
  - 11.2.1.2. Products
  - 11.2.1.3. SWOT analysis
  - 11.2.1.4. Recent Developments
  - 11.2.1.5. Strategies
  - 11.2.1.6. Financials (Based on Availability)
- 11.2.2. CSL Limited (Seqirus)
  - 11.2.2.1. Overview
  - 11.2.2.2. Products
  - 11.2.2.3. SWOT analysis
  - 11.2.2.4. Recent Developments
  - 11.2.2.5. Strategies
  - 11.2.2.6. Financials (Based on Availability)
- 11.2.3. GlaxoSmithKline plc
  - 11.2.3.1. Overview
  - 11.2.3.2. Products
  - 11.2.3.3. SWOT analysis
  - 11.2.3.4. Recent Developments
  - 11.2.3.5. Strategies
  - 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Sanofi
  - 11.2.4.1. Overview
  - 11.2.4.2. Products
  - 11.2.4.3. SWOT analysis
  - 11.2.4.4. Recent Developments
  - 11.2.4.5. Strategies
  - 11.2.4.6. Financials (Based on Availability)
- 11.2.5. SINOVAC
  - 11.2.5.1. Overview
  - 11.2.5.2. Products
  - 11.2.5.3. SWOT analysis
  - 11.2.5.4. Recent Developments
  - 11.2.5.5. Strategies
  - 11.2.5.6. Financials (Based on Availability)
- 11.2.6. BIKEN Co., Ltd.
  - 11.2.6.1. Overview
  - 11.2.6.2. Products
  - 11.2.6.3. SWOT analysis
  - 11.2.6.4. Recent Developments
  - 11.2.6.5. Strategies
  - 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Abbott
  - 11.2.7.1. Overview
  - 11.2.7.2. Products
  - 11.2.7.3. SWOT analysis
  - 11.2.7.4. Recent Developments
  - 11.2.7.5. Strategies
  - 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Viatris Inc.
  - 11.2.8.1. Overview
  - 11.2.8.2. Products
  - 11.2.8.3. SWOT analysis
  - 11.2.8.4. Recent Developments
  - 11.2.8.5. Strategies
  - 11.2.8.6. Financials (Based on Availability)

Product Code: FBI101896

List of Tables

Table 01: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 02: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 03: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
Table 04: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 05: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Region, 2021-2034
Table 06: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 07: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 08: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
Table 09: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 10: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 11: U.S. Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 12: Canada Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 13: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 14: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 15: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
Table 16: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 17: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 18: Germany Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 19: U.K. Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 20: France Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 21: Italy Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 22: Spain Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 23: Scandinavia Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 24: Rest of Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 25: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 26: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 27: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
Table 28: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 29: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 30: Japan Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 31: Korea Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 32: China Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 33: India Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 34: Australia Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 35: Rest of Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 36: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 37: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 38: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
Table 39: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 40: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 41: Brazil Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 42: Mexico Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 43: Rest of Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 44: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 45: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 46: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
Table 47: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 48: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 49: GCC Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 50: South Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
Table 51: Rest of Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034

List of Figures

Figure 01: Global Influenza Vaccine Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 02: Global Influenza Vaccine Market Value Share (%), By Type, 2025 & 2034
Figure 03: Global Influenza Vaccine Market Value Share (%), By Valency, 2025 & 2034
Figure 04: Global Influenza Vaccine Market Value Share (%), By Age Group, 2025 & 2034
Figure 05: Global Influenza Vaccine Market Value Share (%), By Distribution Channel, 2025 & 2034
Figure 06: Global Influenza Vaccine Market Value Share (%), By Region, 2025 & 2034
Figure 07: North America Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 08: North America Influenza Vaccine Market Value Share (%), by Type, 2025
Figure 09: North America Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
Figure 10: North America Influenza Vaccine Market Value Share (%), by Valency, 2025
Figure 11: North America Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
Figure 12: North America Influenza Vaccine Market Value Share (%), by Age Group, 2025
Figure 13: North America Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 14: North America Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 15: North America Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
Figure 16: North America Influenza Vaccine Market Value Share (%), by Country, 2025
Figure 17: Europe Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 18: Europe Influenza Vaccine Market Value Share (%), by Type, 2025
Figure 19: Europe Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
Figure 20: Europe Influenza Vaccine Market Value Share (%), by Valency, 2025
Figure 21: Europe Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
Figure 22: Europe Influenza Vaccine Market Value Share (%), by Age Group, 2025
Figure 23: Europe Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 24: Europe Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 25: Europe Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
Figure 26: Europe Influenza Vaccine Market Value Share (%), by Country, 2025
Figure 27: Asia Pacific Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 28: Asia Pacific Influenza Vaccine Market Value Share (%), by Type, 2025
Figure 29: Asia Pacific Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
Figure 30: Asia Pacific Influenza Vaccine Market Value Share (%), by Valency, 2025
Figure 31: Asia Pacific Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
Figure 32: Asia Pacific Influenza Vaccine Market Value Share (%), by Age Group, 2025
Figure 33: Asia Pacific Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 34: Asia Pacific Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 35: Asia Pacific Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
Figure 36: Asia Pacific Influenza Vaccine Market Value Share (%), by Country, 2025
Figure 37: Latin America Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 38: Latin America Influenza Vaccine Market Value Share (%), by Type, 2025
Figure 39: Latin America Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
Figure 40: Latin America Influenza Vaccine Market Value Share (%), by Valency, 2025
Figure 41: Latin America Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
Figure 42: Latin America Influenza Vaccine Market Value Share (%), by Age Group, 2025
Figure 43: Latin America Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 44: Latin America Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 45: Latin America Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
Figure 46: Latin America Influenza Vaccine Market Value Share (%), by Country, 2025
Figure 47: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 48: Middle East & Africa Influenza Vaccine Market Value Share (%), by Type, 2025
Figure 49: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
Figure 50: Middle East & Africa Influenza Vaccine Market Value Share (%), by Valency, 2025
Figure 51: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
Figure 52: Middle East & Africa Influenza Vaccine Market Value Share (%), by Age Group, 2025
Figure 53: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 54: Middle East & Africa Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 55: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
Figure 56: Middle East & Africa Influenza Vaccine Market Value Share (%), by Country, 2025
Figure 57: Global Influenza Vaccine Market Share (%), 2025

Influenza Vaccine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

Description

Table of Contents

List of Tables

Growth Factors of influenza vaccine Market

Regional Insights

Table of Content

1. Introduction

2. Executive Summary

3. Market Dynamics

4. Key Insights

5. Global Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

6. North America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

7. Europe Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

8. Asia Pacific Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

9. Latin America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

10. Middle East & Africa Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

11. Competitive Analysis

List of Tables

List of Figures